SCHEMBL24257587

SCHEMBL24257587

COC(=O)C1(NC(=O)c2ncc(-c3cccc(Cl)c3)c(C)c2OCc2ccccc2)CCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 1/20 0.39
MAPK1 P28482 1/20 0.37
MAPK10 P53779 1/20 0.37
EGLN1 Q9GZT9 2/20 0.37
VEGFA P15692 1/20 0.37
FLT1 P17948 1/20 0.37
EGLN3 Q9H6Z9 1/20 0.37
PTGER1 P34995 6/20 0.37
CYP2C9 P11712 3/20 0.37
CTSA P10619 2/20 0.36
HIF1A Q16665 1/20 0.36
DGAT2 Q96PD7 1/20 0.36
ADORA1 P30542 1/20 0.36
CYP3A4 P08684 1/20 0.36
GPR132 Q9UNW8 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30453562 1.00 LPAR1 (0.39) LPAR1MAPK1MAPK10EGLN1VEGFA
SCHEMBL24257575 0.91 ADORA1 (0.37) MAPK1MAPK10EGLN1VEGFAFLT1
SCHEMBL30452750 0.91 ADORA1 (0.37) MAPK1MAPK10EGLN1VEGFAFLT1
SCHEMBL30453138 0.90 GPR119 (0.41) MAPK1MAPK10EGLN1VEGFAFLT1
SCHEMBL24257807 0.90 GPR119 (0.41) MAPK1MAPK10EGLN1VEGFAFLT1
SCHEMBL24257584 0.89 MAPK1 (0.39) MAPK1MAPK10EGLN1VEGFAFLT1
SCHEMBL30546863 0.84 EGLN1 (0.41) LPAR1EGLN1VEGFAFLT1EGLN3
SCHEMBL24257523 0.84 EGLN1 (0.41) LPAR1EGLN1VEGFAFLT1EGLN3
SCHEMBL24257583 0.83 GABRA5 (0.41) MAPK1MAPK10EGLN1VEGFAFLT1
SCHEMBL24257585 0.81 PTGER1 (0.47) MAPK1MAPK10PTGER1CYP2C9ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 LPAR1 410/4885MAPK1 255/4885MAPK10 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.